Immatics N.V. (NASDAQ:IMTX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Immatics N.V. (NASDAQ:IMTX) has received a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $20.80.

Several research firms recently issued reports on IMTX. Mizuho set a $25.00 price objective on shares of Immatics in a report on Thursday, February 19th. Chardan Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of Immatics in a report on Tuesday, May 19th. TD Cowen began coverage on shares of Immatics in a report on Tuesday, April 28th. They set a “buy” rating for the company. Jefferies Financial Group began coverage on shares of Immatics in a report on Monday, March 16th. They set a “buy” rating and a $18.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Immatics from a “hold” rating to a “sell” rating in a report on Saturday, May 2nd.

Immatics Trading Down 3.8%

Immatics stock opened at $9.79 on Friday. The company has a market capitalization of $1.31 billion, a P/E ratio of -4.92 and a beta of 1.30. The firm’s fifty day simple moving average is $10.84 and its 200-day simple moving average is $10.28. Immatics has a 1-year low of $5.05 and a 1-year high of $12.41.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.08). The firm had revenue of $8.81 million for the quarter, compared to the consensus estimate of $9.79 million. Immatics had a negative return on equity of 47.36% and a negative net margin of 572.35%. On average, equities research analysts predict that Immatics will post -1.67 earnings per share for the current year.

Hedge Funds Weigh In On Immatics

Large investors have recently bought and sold shares of the stock. Bank of America Corp DE raised its stake in Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after purchasing an additional 2,231 shares during the last quarter. Quarry LP acquired a new position in Immatics during the 4th quarter valued at $84,000. Insigneo Advisory Services LLC acquired a new position in Immatics during the 3rd quarter valued at $103,000. Engineers Gate Manager LP acquired a new position in Immatics during the 2nd quarter valued at $124,000. Finally, Fox Run Management L.L.C. acquired a new position in Immatics during the 4th quarter valued at $129,000. 64.41% of the stock is currently owned by institutional investors and hedge funds.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.